HP
RVNC

Harbourvest Partners’s Revance Therapeutics, Inc. RVNC Stock Holding History

Harbourvest Partners’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-26,365
Closed -$343K – 38
2019
Q3 		$343K Hold
26,365
– – 0.14% 28
2019
Q2 		$342K Sell
26,365
-200
-0.8% -$2.52K 0.13% 28
2019
Q1 		$419K Buy
+26,565
New +$461K 0.15% 27

Other funds holding RVNC

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
EWM
Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
NCM
NovaQuest Capital Management Raleigh, North Carolina $54.3M AUM 163.39% 1-Year Est. Return

Harbourvest Partners's RVNC Position: Q4 2019 in Review

Harbourvest Partners sold out of Revance Therapeutics, Inc. (RVNC) in Q4 2019, closing a stake of 26,365 shares — an estimated $343K sold.

Harbourvest Partners first reported a position in RVNC in Q1 2019 and held it in 3 quarters. The position peaked at $419K in Q1 2019. 134 funds tracked by Wall St. Rank hold RVNC as of Q4 2019.

  • Harbourvest Partners reported no remaining Revance Therapeutics, Inc. position as of Q4 2019 after selling out during the quarter.
  • Harbourvest Partners sold 26,365 Revance Therapeutics, Inc. shares in Q4 2019, an estimated $343K.
  • Harbourvest Partners first reported a position in Revance Therapeutics, Inc. in Q1 2019 and held it in 3 quarters.
  • Harbourvest Partners's Revance Therapeutics, Inc. position peaked at $419K in Q1 2019.
  • 134 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q4 2019.

Based on Harbourvest Partners's 13F filing for Q4 2019, filed 13 Feb 2020.